A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity
Clinical Trial Grant
Awarded By
Janssen Research & Development, LLC
Start Date
August 29, 2024
End Date
August 1, 2027
Awarded By
Janssen Research & Development, LLC
Start Date
August 29, 2024
End Date
August 1, 2027